Physiologic and pharmacologic determinants of vasodilator response

A conceptual framework for rational drug therapy for chronic heart failure

Milton Packer, Thierry H. Le Jemtel

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

This article has attempted to summarize the increasing number of pharmacologic and physiologic variables that are being recognized as important determinants in the response to vasodilator therapy in patients with severe chronic heart failure. It is apparent that a careful consideration of many factors is necessary before proper selection of a specific drug can be made for a specific patient, since not all patients with refractory heart failure demonstrate beneficial hemodynamic and clinical responses to all agents. Each patient presents us with a unique set of physiologic variables; each drug has its own advantages and limitations. Identification of those subgroups of patients most likely to benefit from a specific agent or combination of agents is a major goal for future research. Although a number of hemodynamic variables can be made to improve acutely with a wide variety of vasodilator drugs, well tolerated sustained meaningful clinical benefits are probably observed in relatively few patients. Rational and successful vasodilator therapy is possible only through a highly individualized approach.

Original languageEnglish (US)
Pages (from-to)275-292
Number of pages18
JournalProgress in Cardiovascular Diseases
Volume24
Issue number4
DOIs
StatePublished - 1982

Fingerprint

Vasodilator Agents
Heart Failure
Drug Therapy
Hemodynamics
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Physiologic and pharmacologic determinants of vasodilator response : A conceptual framework for rational drug therapy for chronic heart failure. / Packer, Milton; Le Jemtel, Thierry H.

In: Progress in Cardiovascular Diseases, Vol. 24, No. 4, 1982, p. 275-292.

Research output: Contribution to journalArticle

@article{40528fe3414046f4b3abd995fd9e867d,
title = "Physiologic and pharmacologic determinants of vasodilator response: A conceptual framework for rational drug therapy for chronic heart failure",
abstract = "This article has attempted to summarize the increasing number of pharmacologic and physiologic variables that are being recognized as important determinants in the response to vasodilator therapy in patients with severe chronic heart failure. It is apparent that a careful consideration of many factors is necessary before proper selection of a specific drug can be made for a specific patient, since not all patients with refractory heart failure demonstrate beneficial hemodynamic and clinical responses to all agents. Each patient presents us with a unique set of physiologic variables; each drug has its own advantages and limitations. Identification of those subgroups of patients most likely to benefit from a specific agent or combination of agents is a major goal for future research. Although a number of hemodynamic variables can be made to improve acutely with a wide variety of vasodilator drugs, well tolerated sustained meaningful clinical benefits are probably observed in relatively few patients. Rational and successful vasodilator therapy is possible only through a highly individualized approach.",
author = "Milton Packer and {Le Jemtel}, {Thierry H.}",
year = "1982",
doi = "10.1016/0033-0620(82)90006-8",
language = "English (US)",
volume = "24",
pages = "275--292",
journal = "Progress in Cardiovascular Diseases",
issn = "0033-0620",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Physiologic and pharmacologic determinants of vasodilator response

T2 - A conceptual framework for rational drug therapy for chronic heart failure

AU - Packer, Milton

AU - Le Jemtel, Thierry H.

PY - 1982

Y1 - 1982

N2 - This article has attempted to summarize the increasing number of pharmacologic and physiologic variables that are being recognized as important determinants in the response to vasodilator therapy in patients with severe chronic heart failure. It is apparent that a careful consideration of many factors is necessary before proper selection of a specific drug can be made for a specific patient, since not all patients with refractory heart failure demonstrate beneficial hemodynamic and clinical responses to all agents. Each patient presents us with a unique set of physiologic variables; each drug has its own advantages and limitations. Identification of those subgroups of patients most likely to benefit from a specific agent or combination of agents is a major goal for future research. Although a number of hemodynamic variables can be made to improve acutely with a wide variety of vasodilator drugs, well tolerated sustained meaningful clinical benefits are probably observed in relatively few patients. Rational and successful vasodilator therapy is possible only through a highly individualized approach.

AB - This article has attempted to summarize the increasing number of pharmacologic and physiologic variables that are being recognized as important determinants in the response to vasodilator therapy in patients with severe chronic heart failure. It is apparent that a careful consideration of many factors is necessary before proper selection of a specific drug can be made for a specific patient, since not all patients with refractory heart failure demonstrate beneficial hemodynamic and clinical responses to all agents. Each patient presents us with a unique set of physiologic variables; each drug has its own advantages and limitations. Identification of those subgroups of patients most likely to benefit from a specific agent or combination of agents is a major goal for future research. Although a number of hemodynamic variables can be made to improve acutely with a wide variety of vasodilator drugs, well tolerated sustained meaningful clinical benefits are probably observed in relatively few patients. Rational and successful vasodilator therapy is possible only through a highly individualized approach.

UR - http://www.scopus.com/inward/record.url?scp=0020008055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020008055&partnerID=8YFLogxK

U2 - 10.1016/0033-0620(82)90006-8

DO - 10.1016/0033-0620(82)90006-8

M3 - Article

VL - 24

SP - 275

EP - 292

JO - Progress in Cardiovascular Diseases

JF - Progress in Cardiovascular Diseases

SN - 0033-0620

IS - 4

ER -